ToleroGenics
Developer of tolerance-inducing immunotherapy technologies for allergy and autoimmune diseases. The company focuses on subcutaneous, thermosensitive hydrogel drug-depot delivery of antigen-containing particulate and liposomal adjuvants to recruit and reprogram peripheral antigen-presenting cells, induce regulatory T cells, and achieve long-lasting antigen-specific tolerance. Founded as a public-private partnership with a national immunology institute in July 2016. Holds a portfolio of patents covering composition, delivery and methods for antigen-specific tolerance induction.
Industries
ToleroGenics
Products
Allergy immunotherapy candidates (pipeline)
Development programs for antigen-specific immunotherapies targeting hymenoptera venom allergy, house dust mite allergy, and birch pollen allergy using sustained-release hydrogel delivery of peptide-loaded liposomes or particulate adjuvants.
Allergy immunotherapy candidates (pipeline)
Development programs for antigen-specific immunotherapies targeting hymenoptera venom allergy, house dust mite allergy, and birch pollen allergy using sustained-release hydrogel delivery of peptide-loaded liposomes or particulate adjuvants.
Services
Technology licensing and partnership development
Licensing of tolerance-inducing delivery and formulation technologies to partners and collaboration on product development for allergy and autoimmune indications.
Regulatory and strategic development support
Strategic and regulatory support to advance product candidates toward clinical development and market entry.
Technology licensing and partnership development
Licensing of tolerance-inducing delivery and formulation technologies to partners and collaboration on product development for allergy and autoimmune indications.
Regulatory and strategic development support
Strategic and regulatory support to advance product candidates toward clinical development and market entry.
Expertise Areas
- Tolerance-based immunotherapy development
- Antigen-specific immunotherapy for allergy and autoimmune indications
- Drug delivery: thermosensitive hydrogel depots
- Liposomal and nanoparticle formulation for immune modulation
Key Technologies
- Thermosensitive PLGA-PEG-PLGA hydrogel depots
- Phosphatidylserine (PS) liposomes
- Peptide-loaded liposomal carriers
- PLGA nanoparticles/nanospheres